Search

Your search keyword '"Linassier, Claude"' showing total 231 results
Start Over Author "Linassier, Claude"
231 results on '"Linassier, Claude"'

1. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Author

Naffrichoux, Jérémie, Poupin, Pierre, Pouillot, William, Linassier, Claude, Rioux-Leclercq, Nathalie, De Vries-Brilland, Manon, Mourey, Loïc, Laguerre, Brigitte, Oudard, Stéphane, Gross-Goupil, Marine, Mousset, Coralie, Gravis, Gwenaelle, Rolland, Frédéric, Moise, Laura, Emambux, Sheik, Vassal, Cécile, Zanetta, Sylvie, Penel, Nicolas, Albiges, Laurence, Fromont, Gaëlle, and Cancel, Mathilde

Published
2024
Full Text
View/download PDF

2. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG—AFU 26 NIVOREN

Author

Guilhem-Ducléon, Guillemette, Dalban, Cécile, Negrier, Sylvie, Gravis, Gwenaelle, Laguerre, Brigitte, Chevreau, Christine, Oudard, Stéphane, Barthelemy, Philippe, Ladoire, Sylvain, Boughalem, Elouen, Borchiellini, Delphine, Linassier, Claude, Nenan, Soazig, Flippot, Ronan, Albiges, Laurence, and Goupil, Marine Gross

Published
2023
Full Text
View/download PDF

3. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Author

Dirksen, Uta, Brennan, Bernadette, Le Deley, Marie-Cécile, Cozic, Nathalie, van den Berg, Henk, Bhadri, Vivek, Brichard, Bénédicte, Claude, Line, Craft, Alan, Amler, Susanne, Gaspar, Natalie, Gelderblom, Hans, Goldsby, Robert, Gorlick, Richard, Grier, Holcombe E, Guinbretiere, Jean-Marc, Hauser, Peter, Hjorth, Lars, Janeway, Katherine, Juergens, Heribert, Judson, Ian, Krailo, Mark, Kruseova, Jarmila, Kuehne, Thomas, Ladenstein, Ruth, Lervat, Cyril, Lessnick, Stephen L, Lewis, Ian, Linassier, Claude, Marec-Berard, Perrine, Marina, Neyssa, Morland, Bruce, Pacquement, Hélène, Paulussen, Michael, Randall, R Lor, Ranft, Andreas, Le Teuff, Gwénaël, Wheatley, Keith, Whelan, Jeremy, Womer, Richard, Oberlin, Odile, Hawkins, Douglas S, and Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators

Subjects
Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators, Humans, Bone Neoplasms, Lung Neoplasms, Neoplasm Recurrence, Local, Disease Progression, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Radiotherapy, Adjuvant, Pneumonectomy, Hematopoietic Stem Cell Transplantation, Transplantation, Autologous, Risk Assessment, Risk Factors, Time Factors, Adolescent, Adult, Middle Aged, Child, Child, Preschool, Infant, Europe, Female, Male, Young Adult, Sarcoma, Ewing, Progression-Free Survival, Lung, Stem Cell Research, Cancer, Pediatric, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases.MethodsFrom 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method.ResultsOf 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm.ConclusionIn ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.

Published
2019

4. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status

Author

Carril-Ajuria, Lucía, Colomba, Emeline, Romero-Ferreiro, Carmen, Cerbone, Luigi, Ratta, Raffaele, Barthelemy, Philippe, Vindry, Clarisse, Fléchon, Aude, Cherifi, François, Boughalem, Elouen, Linassier, Claude, Fornarini, Giuseppe, Rebuzzi, Sara E., Gross-Goupil, Marine, Saldana, Carolina, Martin-Soberón, Maricruz, de Velasco, Guillermo, Manneh, Ray, Pernaut, Cristina, Sanchez de Torre, Ana, Flippot, Ronan, Escudier, Bernard, and Albiges, Laurence

Published
2023
Full Text
View/download PDF

5. Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial

Author

Orlando, Valentina, Drubay, Damien, Lavaud, Pernelle, Faivre, Laura, Lesaunier, François, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frédéric, Priou, Frank, Ferrero, Jean-Marc, Houede, Nadine, Mourey, Loic, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Grosse-Goupil, Marine, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Chinet-Charrot, Paule, Legouffe, Eric, Lagrange, Jean-Léon, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Davin, Jean-Louis, Martin, Anne-Laure, Brihoum, Meryem, Culine, Stéphane, Teuff, Gwénaël Le, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

6. Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.

Author

Aubert, Marine, Mathiot, Laurent, Vegas, Hélène, Ouldamer, Lobna, Linassier, Claude, Augereau, Paule, Bocquet, François, Frenel, Jean-Sébastien, and Cancel, Mathilde

Subjects
THERAPEUTIC use of antineoplastic agents, AROMATASE inhibitors, DRUG resistance in cancer cells, OVARIAN tumors, TUMOR grading, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, HORMONE antagonists, OPERATIVE surgery, RESEARCH, WOMEN'S health, PROGRESSION-free survival, ESTROGEN antagonists, PLATINUM, OVERALL survival
Abstract

Background In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When platinum resistant, subsequent lines of chemotherapy are of limited effect and often poorly tolerated, leading to quality of life deterioration. Various studies suggest a hormonal role in ovarian carcinogenesis, with a rationale for endocrine therapy in these cancers. Patients and Methods This multicenter, retrospective study assessed the use of endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020. Results Eighty-one patients with ovarian cancers were included. The median duration of platinum sensitivity was 29 months. We observed a 35% disease control rate with endocrine therapy, and 10% reported symptom improvement. For 19 patients (23.5%), the disease was stabilized for more than 6 months. Median overall survival from diagnosis was 62.6 months. Regarding endocrine therapy predictive factors of response, in a multivariate analysis, 3 factors were statistically significant in favoring progression-free survival: platinum sensitivity (P  = .021), an R0 surgical resection (P  = .020), and the indication for hormone therapy being maintenance therapy (P  = .002) Conclusion This study shows real-life data on endocrine therapy in ovarian cancer. As it is a low-cost treatment with many advantages such as its oral administration and its safety, it may be an option to consider. A perspective lies in the search for cofactors to aim as future therapeutic targets to improve the effectiveness of hormone treatment by means of combination therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.

Author

Chamorey, Emmanuel, Pujalte-Martin, Marc, Ferrero, Jean-Marc, Mahammedi, Hakim, Gravis, Gwenaelle, Roubaud, Guilhem, Beuzeboc, Philippe, Largillier, Remy, Borchiellini, Delphine, Linassier, Claude, Bouges, Hélène, Etienne-Grimaldi, Marie-Christine, Schiappa, Renaud, Gal, Jocelyn, and Milano, Gérard

Subjects
CASTRATION-resistant prostate cancer, ABIRATERONE acetate, PROSTATE cancer patients, CANCER patients, OLDER patients, DOCETAXEL, ACETATES
Abstract

This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. PD-L1 Expression and its Prognostic Value in Metastatic Papillary Renal Cell Carcinoma: Results from a GETUG Multicenter Retrospective Cohort

Author

Naffrichoux, Jérémie, primary, Poupin, Pierre, additional, Pouillot, William, additional, Linassier, Claude, additional, Rioux-Leclercq, Nathalie, additional, De Vries-Brilland, Manon, additional, Mourey, Loic, additional, Laguerre, Brigitte, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Mousset, Coralie, additional, Gravis, Gwenaëlle, additional, Rolland, Frédéric, additional, Moise, Laura, additional, Emambux, Sheik, additional, Vassal, Cécile, additional, Zanetta, Sylvie, additional, Penel, Nicolas, additional, ALBIGES, Laurence, additional, Fromont, Gaelle, additional, and Cancel, Mathilde, additional

Published
2024
Full Text
View/download PDF

10. GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07.

Author

Gross-Goupil, Marine, Frison, Eric, Roubaud, Guilhem, Flechon, Aude, Calcagno, Fabien, Rolland, Frederic, Joly, Florence, Raymond, Anne-Aurelie, Chotard, Guillaume, Barthelemy, Philippe, Pouessel, Damien, Thibault, Constance, Culine, Stephane, Linassier, Claude, and Ravaud, Alain

Published
2024
Full Text
View/download PDF

11. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.

Author

Cancel, Mathilde, Naffrichoux, Jérémie, Poupin, Pierre, Pouillot, William, Linassier, Claude, Rioux-Leclercq, Nathalie, De Vries-Brilland, Manon, Mourey, Loic, Laguerre, Brigitte, Oudard, Stephane, Gross-Goupil, Marine, Gravis, Gwenaelle, Rolland, Frederic, Moise, Laura, Emambux, Sheik Muhummud Fardeen, Vassal, Cecile, Zanetta, Sylvie, Penel, Nicolas, Albiges, Laurence, and Fromont, Gaelle

Published
2024
Full Text
View/download PDF

12. Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Etude des Tumeurs Uro-Genitales) study.

Author

Carneiro, Florian, Vinceneux, Armelle, Larroquette, Mathieu, Rony, Maelle, Carril, Lucia, Laguerre, Brigitte, Blazevic, Ilfad, Barthelemy, Philippe, Teyssonneau, Diego, Goujon, Morgan, Linassier, Claude, Thiery-Vuillemin, Antoine, Roubaud, Guilhem, Mourey, Loic, Albiges, Laurence, Gravis, Gwenaelle, Gross-Goupil, Marine, and Cancel, Mathilde

Published
2024
Full Text
View/download PDF

13. Figure S1 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial

Author

Mauge, Laetitia, primary, Mejean, Arnaud, primary, Fournier, Laure, primary, Pereira, Helena, primary, Etienne-Grimaldi, Marie-Christine, primary, Levionnois, Emeline, primary, Caty, Armelle, primary, Abadie-Lacourtoisie, Sophie, primary, Culine, Stéphane, primary, Le Moulec, Sylvestre, primary, Linassier, Claude, primary, Théodore, Christine, primary, Ravaud, Alain, primary, Albiges, Laurence, primary, Grine, Abel, primary, Tartour, Eric, primary, Milano, Gérard, primary, Gille, Anne-Sophie, primary, Verkarre, Virginie, primary, Helley, Dominique, primary, and Oudard, Stéphane, primary

Published
2023
Full Text
View/download PDF

14. Table S4 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial

Author

Mauge, Laetitia, primary, Mejean, Arnaud, primary, Fournier, Laure, primary, Pereira, Helena, primary, Etienne-Grimaldi, Marie-Christine, primary, Levionnois, Emeline, primary, Caty, Armelle, primary, Abadie-Lacourtoisie, Sophie, primary, Culine, Stéphane, primary, Le Moulec, Sylvestre, primary, Linassier, Claude, primary, Théodore, Christine, primary, Ravaud, Alain, primary, Albiges, Laurence, primary, Grine, Abel, primary, Tartour, Eric, primary, Milano, Gérard, primary, Gille, Anne-Sophie, primary, Verkarre, Virginie, primary, Helley, Dominique, primary, and Oudard, Stéphane, primary

Published
2023
Full Text
View/download PDF

16. Natural history of patients with muscle metastases from renal cell carcinoma: Results of the French national ARTEMIS study.

Author

Wespiser, Mylene, primary, Carril-Ajuria, Lucia, additional, Ilfad, Blazevic, additional, Thibault, Constance, additional, Flechon, Aude, additional, Martin, Sophie, additional, Laramas, Mathieu, additional, Borchiellini, Delphine, additional, Simon, Camille, additional, Mahammedi, Hakim, additional, Linassier, Claude, additional, Goujon, Morgan, additional, Zaibet, Sonia, additional, Rolland, Frederic, additional, Albiges, Laurence, additional, Meurisse, Aurelia, additional, Falcoz, Antoine, additional, and Thiery-Vuillemin, Antoine, additional

Published
2023
Full Text
View/download PDF

17. Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer

Author

Ferrero, Jean-Marc, primary, Mahammedi, Hakim, additional, Gravis, Gwenaelle, additional, Roubaud, Guilhem, additional, Beuzeboc, Philippe, additional, Largillier, Remi, additional, Borchiellini, Delphine, additional, Linassier, Claude, additional, Ebran, Nathalie, additional, Pace-Loscos, Tanguy, additional, Etienne-Grimaldi, Marie-Christine, additional, Schiappa, Renaud, additional, Gal, Jocelyn, additional, and Milano, Gérard, additional

Published
2023
Full Text
View/download PDF

18. Gastrointestinal Metastases in Renal Cell Carcinoma: A Retrospective Multicenter GETUG (Groupe D’Étude Des Tumeurs Uro-Génitales) Study

Author

Carneiro, Florian, primary, Vinceneux, Armelle, additional, Larroquette, Mathieu, additional, Rony, Maelle, additional, Carril, Lucia, additional, Laguerre, Brigitte, additional, Blazevic, Ilfad, additional, BARTHELEMY, Philippe, additional, Teyssonneau, Diego, additional, Goujon, Morgan, additional, Linassier, Claude, additional, Thierry-Vuillemin, Antoine, additional, Roubaud, Guilhem, additional, Mourey, Loic, additional, ALBIGES, Laurence, additional, Gravis, Gwenaëlle, additional, Gross-Goupil, Marine, additional, and Cancel, Mathilde, additional

Published
2023
Full Text
View/download PDF

19. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Author

Fizazi, Karim, Faivre, Laura, Lesaunier, François, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frédéric, Priou, Frank, Ferrero, Jean-Marc, Houede, Nadine, Mourey, Loïc, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Ravaud, Alain, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Chinet-Charrot, Paule, Legouffe, Eric, Lagrange, Jean-Léon, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Davin, Jean-Louis, Martin, Anne-Laure, Habibian, Muriel, Laplanche, Agnès, and Culine, Stéphane

Published
2015
Full Text
View/download PDF

20. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

Author

Fizazi, Karim, Pagliaro, Lance, Laplanche, Agnes, Fléchon, Aude, Mardiak, Josef, Geoffrois, Lionnel, Kerbrat, Pierre, Chevreau, Christine, Delva, Remy, Rolland, Frederic, Theodore, Christine, Roubaud, Guilhem, Gravis, Gwenaëlle, Eymard, Jean-Christophe, Malhaire, Jean-Pierre, Linassier, Claude, Habibian, Muriel, Martin, Anne-Laure, Journeau, Florence, Reckova, Maria, Logothetis, Christopher, and Culine, Stephane

Published
2014
Full Text
View/download PDF

21. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Author

Gravis, Gwenaelle, Fizazi, Karim, Joly, Florence, Oudard, Stéphane, Priou, Franck, Esterni, Benjamin, Latorzeff, Igor, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Rolland, Fréderic, Théodore, Christine, Deplanque, Gael, Ferrero, Jean Marc, Pouessel, Damien, Mourey, Loïc, Beuzeboc, Philippe, Zanetta, Sylvie, Habibian, Muriel, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Labourey, Jean Luc, Machiels, Jean Pascal, El Kouri, Claude, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, and Soulie, Michel

Published
2013
Full Text
View/download PDF

22. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Author

Fizazi, Karim, Lesaunier, Francois, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frederic, Priou, Frank, Ferrero, Jean-Marc, Houedé, Nadine, Mourey, Loïc, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Ravaud, Alain, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Lagrange, Jean-Léon, Chinet-Charrot, Paule, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Geneve, Jean, Davin, Jean-Louis, Tournay, Elodie, and Culine, Stephane

Published
2012
Full Text
View/download PDF

23. Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS).

Author

Carril, Lucia, primary, Colomba, Emeline, additional, Romero-Ferreiro, Carmen, additional, Cerbone, Luigi, additional, Ratta, Raffaele, additional, Barthélémy, Philippe, additional, Vindry, Clarisse, additional, Cherifi, Francois, additional, Boughalem, Elouen, additional, Linassier, Claude, additional, Fornarini, Giuseppe, additional, Gross-Goupil, Marine, additional, Saldana, Carolina, additional, Martin Soberón, Maria Cruz, additional, de Velasco, Guillermo, additional, Pernaut, Cristina, additional, Alves Costa Silva, Carolina, additional, Flippot, Ronan, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2022
Full Text
View/download PDF

25. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales)

Author

Cancel, Mathilde, primary, Fromont, Gaelle, additional, Blonz, Cyriac, additional, Chevreau, Christine, additional, Rioux-Leclercq, Nathalie, additional, Laguerre, Brigitte, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Gravis, Gwenaelle, additional, Goldwasser, François, additional, Rolland, Frédéric, additional, Delva, Rémy, additional, Moise, Laura, additional, Emambux, Sheik, additional, Vassal, Cécile, additional, Zanetta, Sylvie, additional, Penel, Nicolas, additional, Fléchon, Aude, additional, Barthélémy, Philippe, additional, Saldana, Carolina, additional, Lefort, Félix, additional, Escudier, Bernard, additional, Linassier, Claude, additional, and Albiges, Laurence, additional

Published
2021
Full Text
View/download PDF

26. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Author

Méjean, Arnaud, primary, Ravaud, Alain, additional, Thezenas, Simon, additional, Chevreau, Christine, additional, Bensalah, Karim, additional, Geoffrois, Lionnel, additional, Thiery-Vuillemin, Antoine, additional, Cormier, Luc, additional, Lang, Hervé, additional, Guy, Laurent, additional, Gravis, Gwenaelle, additional, Rolland, Frederic, additional, Linassier, Claude, additional, Lechevallier, Eric, additional, Oudard, Stephane, additional, Laguerre, Brigitte, additional, Gross-Goupil, Marine, additional, Bernhard, Jean Christophe, additional, Colas, Sandra, additional, Albiges, Laurence, additional, Lebret, Thierry, additional, Treluyer, Jean-Marc, additional, Timsit, Marc-Olivier, additional, and Escudier, Bernard, additional

Published
2021
Full Text
View/download PDF

27. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study

Author

Joly, Florence, Delva, Remy, Mourey, Loïc, Sevin, Emmanuel, Bompas, Emmanuelle, Vedrine, Lionel, Ravaud, Alain, Eymard, Jean-Christophe, Tubiana-Mathieu, Nicole, Linassier, Claude, Houede, Nadine, Guillot, Aline, Ringensen, François, Cojocarasu, Oana, Valenza, Bruno, Leconte, Alexandra, Lheureux, Stéphanie, Clarisse, Bénédicte, and Oudard, Stéphane

Published
2015
Full Text
View/download PDF

28. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

Author

Oudard, Stéphane, Rixe, Olivier, Beuselinck, Benoit, Linassier, Claude, Banu, Eugeniu, Machiels, Jean-Pascal, Baudard, Marion, Ringeisen, François, Velu, Thierry, Lefrere-Belda, Marie-Aude, Limacher, Jean-Marc, Fridman, W. H., Azizi, Michel, Acres, Bruce, and Tartour, Eric

Published
2011
Full Text
View/download PDF

32. Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years

Author

Marec-Berard, Perrine, primary, Laurence, Valérie, additional, Occean, Bob-Valéry, additional, Ray-Coquard, Isabelle, additional, Linassier, Claude, additional, Corradini, Nadège, additional, Collard, Olivier, additional, Chaigneau, Loïc, additional, Cupissol, Didier, additional, Kerbrat, Pierre, additional, Saada-Bouzid, Esma, additional, Delcambre, Corinne, additional, Gouin, François, additional, Guillemet, Cécile, additional, Jimenez, Marta, additional, Lervat, Cyril, additional, Gaspar, Nathalie, additional, Le Deley, Marie-Cécile, additional, Brugieres, Laurence, additional, and Piperno-Neumann, Sophie, additional

Published
2020
Full Text
View/download PDF

37. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Dirksen, Uta, Brennan, Bernadette, Le Deley, Marie-Cécile, Cozic, Nathalie, van den Berg, Henk, Bhadri, Vivek, Brichard, Bénédicte, Claude, Line, Craft, Alan, Amler, Susanne, Gaspar, Natalie, Gelderblom, Hans, Goldsby, Robert, Gorlick, Richard, Grier, Holcombe E, Guinbretiere, Jean-Marc, Hauser, Peter, Hjorth, Lars, Janeway, Katherine, Juergens, Heribert, Judson, Ian, Krailo, Mark, Kruseova, Jarmila, Kuehne, Thomas, Ladenstein, Ruth, Lervat, Cyril, Lessnick, Stephen L, Lewis, Ian, Linassier, Claude, Marec-Berard, Perrine, Marina, Neyssa, Morland, Bruce, Pacquement, Hélène, Paulussen, Michael, Randall, R Lor, Ranft, Andreas, Le Teuff, Gwénaël, Wheatley, Keith, Whelan, Jeremy, Womer, Richard, Oberlin, Odile, Hawkins, Douglas S, Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Dirksen, Uta, Brennan, Bernadette, Le Deley, Marie-Cécile, Cozic, Nathalie, van den Berg, Henk, Bhadri, Vivek, Brichard, Bénédicte, Claude, Line, Craft, Alan, Amler, Susanne, Gaspar, Natalie, Gelderblom, Hans, Goldsby, Robert, Gorlick, Richard, Grier, Holcombe E, Guinbretiere, Jean-Marc, Hauser, Peter, Hjorth, Lars, Janeway, Katherine, Juergens, Heribert, Judson, Ian, Krailo, Mark, Kruseova, Jarmila, Kuehne, Thomas, Ladenstein, Ruth, Lervat, Cyril, Lessnick, Stephen L, Lewis, Ian, Linassier, Claude, Marec-Berard, Perrine, Marina, Neyssa, Morland, Bruce, Pacquement, Hélène, Paulussen, Michael, Randall, R Lor, Ranft, Andreas, Le Teuff, Gwénaël, Wheatley, Keith, Whelan, Jeremy, Womer, Richard, Oberlin, Odile, Hawkins, Douglas S, and Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators

Abstract

PURPOSE: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventiona

Published
2019

42. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

Author

Mejean, Arnaud, primary, Thezenas, Simon, additional, Chevreau, Christine, additional, Bensalah, Karim, additional, Geoffrois, Lionnel, additional, Thiery-Vuillemin, Antoine, additional, Cormier, Luc, additional, Lang, Herve, additional, Guy, Laurent, additional, Gravis, Gwenaelle, additional, Rolland, Frederic, additional, Linassier, Claude, additional, Timsit, Marc-Olivier, additional, Albiges, Laurence, additional, Oudard, Stephane, additional, Lebret, Thierry, additional, Treluyer, jean-Marc, additional, Colas, Sandra, additional, Escudier, Bernard, additional, and Ravaud, Alain, additional

Published
2019
Full Text
View/download PDF

43. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy

Author

Oudard, Stéphane, primary, Latorzeff, Igor, additional, Caty, Armelle, additional, Miglianico, Laurent, additional, Sevin, Emmanuel, additional, Hardy-Bessard, Anne Claire, additional, Delva, Remy, additional, Rolland, Frédéric, additional, Mouret, Loic, additional, Priou, Franck, additional, Beuzeboc, Philippe, additional, Gravis, Gwenaelle, additional, Linassier, Claude, additional, Gomez, Philippe, additional, Voog, Eric, additional, Muracciole, Xavier, additional, Abraham, Christine, additional, Banu, Eugeniu, additional, Ferrero, Jean-Marc, additional, Ravaud, Alain, additional, Krakowski, Ivan, additional, Lagrange, Jean-Léon, additional, Deplanque, Gaël, additional, Zylberait, David, additional, Bozec, Laurence, additional, Houede, Nadine, additional, Culine, Stéphane, additional, and Elaidi, Reza, additional

Published
2019
Full Text
View/download PDF

44. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia

Author

Ifrah, Norbert, Witz, Francis, Jouet, Jean-Pierre, Francois, Sylvie, Lamy, Thierry, Linassier, Claude, Pignon, Bernard, Berthou, Christian, Guyotat, Denis, Cahn, Jean-Yves, and Harousseau, Jean-Luc

Subjects
Lymphocytic leukemia, Granulocyte-macrophage colony stimulating factor -- Health aspects, Health
Published
1999

46. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean-Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, Fizazi, Karim, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean-Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, and Fizazi, Karim

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for mCNPC. OBJECTIVE: To investigate the efficacy and tolerance of subsequent treatments in patients treated upfront with chemo-hormonal therapy for mCNPC. DESIGN, SETTING, AND PARTICIPANTS: Retrospective data from the GETUG-AFU 15 phase 3 trial were collected for treatments received for mCRPC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For the first three lines of salvage treatment for mCRPC we investigated the biochemical progression-free survival, maximum prostate-specific antigen (PSA) decline, overall survival, and tolerance. RESULTS AND LIMITATIONS: Overall, 245 patients received at least one treatment for mCRPC. For docetaxel used in first-line, a PSA decline ≥50% was observed in 25/66 (38%) and in 4/20 patients (20%) who had received upfront ADT alone and ADT plus docetaxel (p=0.14). The median biochemical progression-free survival was 6.0 mo (95% confidence interval: 3.6-7.7) and 4.1 mo (95% confidence interval: 1.3-4.9), respectively. For docetaxel used in first- or second-line, a PSA decline ≥50% was observed in 36/80 (45%) and in 4/29 patients (14%) who had received upfront ADT alone and ADT plus docetaxel (p=0.07). PSA declines ≥50% were observed with bicalutamide in 12/28 (43%) and 4/23 patients (17%) who had received upfront ADT alone and ADT plus docetaxel. Among men treated upfront with ADT plus docetaxel who received abiraterone or enzalutamide for mCRPC, 10/19 patients (53%) achieved a PSA decline ≥50%. Few grade 3-4 events occurred. Study limitations include the observational design and retrospective characteristics of this analysis, without standardized therapeutic salv

Published
2018

47. Three courses of high dose therapy: feasibility in the treatment of multiple myeloma - a 'France Autogreffe' study

Author

Colombat, Philippe, Milpied, Noel, Laporte, Jean Phillipe, Casassus, Philippe, Linassier, Claude, and Harousseau, Jean Luc

Subjects
Multiple myeloma, Chemotherapy -- Dosage and administration, Bone marrow -- Transplantation, Health
Abstract

Background. High dose melphalan is used widely in the treatment of multiple myeloma (MM) and in the conditioning regimen of autologous stem cell transplantation (ABST). Double courses of high dose melphalan and double autologous bone marrow transplantation (ABMT) programs also have been widely reported. However, there are no data about the feasibility and efficacy of three courses of high dose therapy, such as high dose melphalan or powerful therapies in the treatment of malignant disease. Methods. In 1991, a retrospective study in France was inititated to evaluate how many patients with MM had received three courses of high dose therapy with or without hematopoietic stem cell rescue. Results. This small study of six patients with multiple myeloma showed that three courses of high dose therapy with or without stem cell rescue can be performed with relative safety. Stem cell rescue appears to shorten the duration of aplasia. In terms of antitumor response, long term response could be obtained in patients with MM that responded to the first course of high dose melphalan. Conclusions. High dose therapy with or without ABMT can be an effective treatment for relapse in a subgroup of patients with MM who respond to high dose melphalan as initial treatment. Cancer 1994; 74:2930-4.

Published
1994

48. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial

Author

Mauge, Laetitia, primary, Mejean, Arnaud, additional, Fournier, Laure, additional, Pereira, Helena, additional, Etienne-Grimaldi, Marie-Christine, additional, Levionnois, Emeline, additional, Caty, Armelle, additional, Abadie-Lacourtoisie, Sophie, additional, Culine, Stéphane, additional, Le Moulec, Sylvestre, additional, Linassier, Claude, additional, Théodore, Christine, additional, Ravaud, Alain, additional, Albiges, Laurence, additional, Grine, Abel, additional, Tartour, Eric, additional, Milano, Gérard, additional, Gille, Anne-Sophie, additional, Verkarre, Virginie, additional, Helley, Dominique, additional, and Oudard, Stéphane, additional

Published
2018
Full Text
View/download PDF

49. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Author

Méjean, Arnaud, primary, Ravaud, Alain, additional, Thezenas, Simon, additional, Colas, Sandra, additional, Beauval, Jean-Baptiste, additional, Bensalah, Karim, additional, Geoffrois, Lionnel, additional, Thiery-Vuillemin, Antoine, additional, Cormier, Luc, additional, Lang, Hervé, additional, Guy, Laurent, additional, Gravis, Gwenaelle, additional, Rolland, Frederic, additional, Linassier, Claude, additional, Lechevallier, Eric, additional, Beisland, Christian, additional, Aitchison, Michael, additional, Oudard, Stephane, additional, Patard, Jean-Jacques, additional, Theodore, Christine, additional, Chevreau, Christine, additional, Laguerre, Brigitte, additional, Hubert, Jacques, additional, Gross-Goupil, Marine, additional, Bernhard, Jean-Christophe, additional, Albiges, Laurence, additional, Timsit, Marc-Olivier, additional, Lebret, Thierry, additional, and Escudier, Bernard, additional

Published
2018
Full Text
View/download PDF

50. Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Author

Chaigneau, Loïc, primary, Patrikidou, Anna, additional, Ray-Coquard, Isabelle, additional, Valentin, Thibaud, additional, Linassier, Claude, additional, Bay, Jacques Olivier, additional, Moureau Zabotto, Laurence, additional, Bompas, Emmanuelle, additional, Piperno-Neumann, Sophie, additional, Penel, Nicolas, additional, Alcindor, Thierry, additional, Laigre, Maryline, additional, Guillemet, Cecile, additional, Salas, Sebastien, additional, Hugli, Anne, additional, Domont, Julien, additional, Sunyach, Marie Pierre, additional, Lecesne, Axel, additional, Blay, Jean Yves, additional, Nerich, Virginie, additional, and Isambert, Nicolas, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results